Ciba Vision's Focus
This article was originally published in The Gray Sheet
Executive Summary
Extended-wear, disposable Focus Night & Day soft contact lenses will be priced "competitively" with the cost of wearing and cleaning ordinary disposables, the Novartis unit says following FDA approval Oct. 12. The lenses are the first to be approved for continuous 30-day wear, as opposed to the conventional seven-day maximum. Made of lotrafilcon A, the Focus is available for eyes +0.25 diopters to +6 D in 0.25 D increments, -0.25 D to -8 D eyes in 0.25 D steps and -8.5 D to -10 D eyes in 0.5 D steps. FDA's Ophthalmic Devices Panel recommended approval in July (1"The Gray Sheet" July 23, 2001, p. 27). A required postmarket study will evaluate long-term risk of infection
You may also be interested in...
Bausch & Lomb PureVision 30-Day Indication Receives FDA Go-Ahead
A hearing to address patent infringement allegations by Bausch & Lomb over Ciba Vision's extended-wear contact lenses will take place in January in Rochester, New York federal court, according to B&L
Bausch & Lomb PureVision 30-Day Indication Receives FDA Go-Ahead
A hearing to address patent infringement allegations by Bausch & Lomb over Ciba Vision's extended-wear contact lenses will take place in January in Rochester, New York federal court, according to B&L
Ciba Vision 30-Day Extended Wear Contact Lenses Get Panel Nod
Ciba Vision's Focus Night & Day contact lens indication statement should not include a claim of reduced dryness compared to hydrogel soft contacts, FDA's Ophthalmic Devices Panel recommended at a July 20 meeting in Rockville, Maryland.